Open AccessCopy number alterations are associated with metastatic-lethal progression in prostate cancer
Author(s) -
Xiaoyu Wang,
Catherine S. Grasso,
Kristina M. Jordahl,
Suzanne Kolb,
Yaw A. Nyame,
Jonathan L. Wright,
Elaine A. Ostrander,
Dean A. Troyer,
Raymond S. Lance,
Ziding Feng,
James Y. Dai,
Janet L. Stanford
Publication year - 2020
Publication title -
prostate cancer and prostatic diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2
H-Index - 64
eISSN - 1476-5608
pISSN - 1365-7852
DOI - 10.1038/s41391-020-0212-8
Subject(s) - medicine , prostate cancer , prostatectomy , cohort , oncology , biochemical recurrence , dna methylation , cancer , field cancerization , metastasis , primary tumor , gene , biochemistry , gene expression , chemistry
Aside from Gleason score few factors accurately identify the subset of prostate cancer (PCa) patients at high risk for metastatic progression. We hypothesized that copy number alterations (CNAs), assessed using CpG methylation probes on Illumina Infinium® Human Methylation450 (HM450K) BeadChip arrays, could identify primary prostate tumors with potential to develop metastatic progression.